Reports Q4 revenue $21.61M, consensus $20.06M. "In 2022, we focused on advancing our internal portfolio of XmAb drug candidates, including the ongoing Phase 2 studies for vudalimab in combination with chemotherapy and as a monotherapy in prostate and gynecological tumors. We also advanced XmAb564, our regulatory T-cell targeting cytokine, into a multiple-ascending dose study in atopic dermatitis and psoriasis, following encouraging single-dose data that showed potentially differentiated durability at boosting target cells," said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. "We continue to leverage our XmAb technologies and protein engineering capabilities, both internally and with partners, to address challenging areas of biology and continually grow our portfolio. We initiated Phase 1 studies for two novel T-cell engagers, XmAb819, our 2+1 formatted CD3 bispecific for renal cell carcinoma, and XmAb808, our first internal bispecific targeting CD28, a new class of anti-tumor agent that we are at the forefront of developing."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on XNCR:
